

## OSBPL2 antibody

**Cat. No. GTX00814**

<b>Host</b>	Rabbit
<b>Clonality</b>	Polyclonal
<b>Isotype</b>	IgG
<b>Applications</b>	WB, ICC/IF
<b>Reactivity</b>	Human

**Package**  
100 µl

## Applications

**Application Note**

\*Optimal dilutions/concentrations should be determined by the researcher.

Suggested dilution	Recommended dilution
WB	1:500-1:2000
ICC/IF	1:100-1:500

Not tested in other applications.

**Calculated MW** 55 kDa. ([Note](#))

## Properties

<b>Form</b>	Liquid
<b>Buffer</b>	PBS, 150mM NaCl, 50% Glycerol
<b>Preservative</b>	0.02% Sodium azide
<b>Storage</b>	Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
<b>Concentration</b>	1 mg/ml (Please refer to the vial label for the specific concentration.)
<b>Immunogen</b>	A synthesized peptide derived from human OSBPL2, corresponding to a region within C-terminal amino acids.
<b>Purification</b>	Purified by antigen-affinity chromatography From serum
<b>Conjugation</b>	Unconjugated

**Note**


For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.



For full product information, images and publications, please visit our [website](#).

DATA IMAGES



**GTX00814 ICC/IF Image**


ICC/IF analysis of PFA-fixed HeLa cells using GTX00814 OSBPL2 Antibody.

Red : Primary antibody

Green : Tubulin


Permeabilization : 0.1% Triton X-100

Dilution : 1:200



**GTX00814 WB Image**

WB analysis of myeloma cells using OSBPL2 Antibody. The lane on the left was treated with blocking peptide.



**GTX00814 WB Image**

WB analysis of HeLa cell lysate using GTX00814 OSBPL2 Antibody. The lane on the left was treated with blocking peptide.



For full product information, images and publications, please visit our [website](#).